Zai Lab
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Zai Lab concentrates its licensing activity in Oncology, Immunology, and InfectiousDisease. Zai Lab pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $339M. Most recent activity: 2025.
Pipeline coverage & gaps
Zai Lab has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 11 | $38M | $247M |
| Collaboration | 4 | $38M | $595M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | ZB001 | Zenas BioPharma | thyroid eye disease | unknown | $10M | $106M |
| 2023 | Nuzyra (omadacycline) | Paratek Pharmaceuticals | Bacterial skin infections, pneumonia | approved | $15M | $150M |
| 2022 | TIVDAK | Seagen Inc. | recurrent or metastatic cervical cancer | phase_3 | $30M | $293M |
| 2022 | TIVDAK (tisotumab vedotin) | Seagen Inc. | recurrent or metastatic cervical cancer | approved | $30M | $293M |
| 2022 | TIVDAK (tisotumab vedotin) | Seagen | locally advanced or metastatic urothelial cancer | approved | $30M | $293M |
| 2021 | BLU-945 and BLU-701 | Blueprint Medicines Corporation | nsclc | phase_1 | $25M | $615M |
| 2021 | KarXT | Karuna Therapeutics | schizophrenia, psychosis in Alzheimer's disease | phase_3 | $35M | $187M |
| 2021 | — | MacroGenics | solid_tumor | preclinical | $25M | $1.5B |
| 2021 | adagrasib | Mirati Therapeutics, Inc. | nsclc, colorectal cancer, pancreatic cancer, other KRAS G12C-mutated solid tumors | phase_2 | $65M | $338M |
| 2021 | Adagrasib (MRTX849) | Mirati Therapeutics | KRAS G12C-mutant tumors | phase_2 | $65M | $338M |
| 2021 | Qinlock (ripretinib) | Deciphera Pharmaceuticals | Gastrointestinal Stromal Tumors (GIST) | approved | $20M | $192M |
| 2021 | efgartigimod | argenx | generalized myasthenia gravis | phase_3 | $75M | $175M |
| 2021 | efgartigimod | argenx SE | generalized myasthenia gravis | phase_3 | $75M | $175M |
| 2020 | Mirvetuximab soravtansine | ImmunoGen | ovarian cancer | phase_2 | $40M | $305M |
| 2020 | repotrectinib | Turning Point Therapeutics, Inc. | solid_tumor | phase_1 | $25M | $176M |
How this is computed
For each Zai Lab deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.194, clamped to [0.7, 1.5].